EXECUTIVE ENGAGEMENTS
OUTREACH
432
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
86
Interactions with Platform & by Email
PARTICIPANTS
17
Unique # Participated
VALIDATIONS
8
Responses Validated*
COMPETITORS
46
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
147
PAGES
223
EDITION
7
PRICE
USD $4950
HIGHLIGHTS
Amid the COVID-19 crisis, the global market for Plasma Protease C1-inhibitor Treatment estimated at US$2.6 Billion in the year 2020, is projected to reach a revised size of US$9.1 Billion by 2027, growing at a CAGR of 19.8% over the analysis period 2020-2027. C1-Inhibitor, one of the segments analyzed in the report, is projected to record a 18.2% CAGR and reach US$4.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Kallikrein Inhibitor (Kalbitor) segment is readjusted to a revised 19.9% CAGR for the next 7-year period.
The Plasma Protease C1-inhibitor Treatment market in the U.S. is estimated at US$765.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 19.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.6% and 17.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 14.6% CAGR.
In the global Selective Bradykinin B2 Receptor Antagonist (Firazyr)) segment, USA, Canada, Japan, China and Europe will drive the 23.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$406.9 Million in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.1 Billion by the year 2027.
SELECT PLAYERS
AbbVie; Alexion; Argenx; Bluebird Bio; Bristol-Myers Squibb/Celgene; CSL Limited; FibroGen; Gilead; GlaxoSmithKline; Novartis; Pharming Group N.V.; Sanquin; Shire plc; Vertex
SEGMENTS
» Distribution Channel (Hospital Pharmacies, Independent Pharmacies) » Dosage Type (Lyophilized, Liquid/Injectable) » Drug Class (C1-Inhibitor, Kallikrein Inhibitor (Kalbitor), Selective Bradykinin B2 Receptor Antagonist (Firazyr)))
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Plasma Protease C1-inhibitor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for C1-Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for C1-Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for C1-Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Kallikrein Inhibitor (Kalbitor) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Kallikrein Inhibitor (Kalbitor) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Kallikrein Inhibitor (Kalbitor) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Selective Bradykinin B2 Receptor Antagonist (Firazyr)) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Selective Bradykinin B2 Receptor Antagonist (Firazyr)) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Selective Bradykinin B2 Receptor Antagonist (Firazyr)) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Lyophilized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Lyophilized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Lyophilized by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Liquid/Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Liquid/Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Liquid/Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Independent Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Independent Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Independent Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 46 |
Tapping into New Geographical Markets is a Great Way to Grow!
What's Your Addressable Opportunity in the Plasma Protease C1-inhibitor Treatment Market?
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com